Abstract：Objective To explore the application effect of Edaravone in patients with acute cerebral infarction (ACI).Methods A total of 64 ACI patients admitted to the Second People′s Hospital of Yichun City from September 2019 to March 2021 were selected as the study subjects,and they were divided into study group and control group according to random number table method,with 32 patients in each group.The control group received Aspirin routine treatment,the study group plus Edaravone treatment.The clinical efficacy,serological indexes,degree of neurological deficit and adverse reactions were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group,the difference was statistically significant (P＜0.05).Before treatment,there were no significant differences in the levels of brain natriuretic peptide (BNP),C-reactive protein (CRP) and homocysteine (Hcy)between two groups (P＞0.05).After treatment,the levels of BNP,CRP and Hcy in the study group were lower than those in the control group,and the differences were statistically significant (P＜0.05).Before treatment,there was no significant difference in the scores of National Institutes of Health stroke scale (NIHSS) between the two groups (P＞0.05).After treatment,NIHSS score of the study group was lower than that of the control group,and the difference was statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Edaravone can effectively improve the levels of serum BNP,CRP and Hcy in patients with acute cerebral infarction,reduce inflammatory reaction and facilitate the recovery of neurological function.
京公网安备 11010502046607号